

CURRICULUM VITAE

PERSONAL



NAME(姓名，含英譯)

黃莉茵

Li Ying (Grace) Huang, Pharmacist, MSc, Ph.D

PROFESSIONAL APPOINTMENT (現職，含英譯)

- 財團法人醫藥品查驗中心醫藥科技評估組組長/資深研究員
Director, Division of Health Technology Assessment Center for Drug Evaluation, Taiwan
- 2020年6月迄今 國際醫療科技評估網絡組織(HTAi)理監事會理事(board of director)
(<https://htai.org/>)
HTAi Board Member

EDUCATION(學歷)

國立臺灣大學公共衛生學院健康政策與管理研究所博士
國立臺灣大學公共衛生學院健康政策與管理研究所碩士逕升博士
國立臺灣大學藥學系碩士
台北醫學大學藥學系學士

WORKING EXPERIENCE (經歷)

2016年6月-2018年6月國際官方HTA組織聯盟 (INAHTA) 理監事會理事(board of director)
2019年6月-2021年6月 國際官方HTA組織聯盟(INAHTA) 理監事會理事(board of director)
財團法人新光吳火獅紀念醫院藥劑部/臨床藥學組/組長/感染科臨床藥師
台北市立聯合醫院松德院區藥劑科總藥師

MAJOR RESEARCH AREA(研究領域)

醫療科技評估 (HTA)、相對療效評估、系統性文獻回顧及統合分析、運用資料庫進行藥物處方趨勢分析、國際合作、臨床藥學、流病學及台灣成人糖尿病照護臨床治療慣性 (Therapeutic inertia) 之醫療提供者影響因素分析 (Therapeutic inertia among adult DM patients in Taiwan focusing on associated factors of health care provider)。

PUBLICATION(In the nearest 5 years)(發表、出版物)

1. **Huang LY**, Shau WY, Chen HC, Su S, Yang MC, Yeh HL, Lai MS. Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: a six-year study. *Eur Rev Med Pharmacol Sci*. 2013 Feb;17(3):410-9. [SCI]
2. **Huang LY**, Lai MS. Therapeutic inertia and intensified treatment in diabetes prescription patterns: A nationwide population-based study. 2014. 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) (Abstract) 獲選 Top 8 of the day, Spotlight Session presentation.
3. 博士論文: 探討影響台灣成人糖尿病照護臨床治療慣性 (Therapeutic inertia) 之醫療提供者影響因素分析 (Therapeutic inertia among adult DM patients in Taiwan focusing on associated factors of health care provider). 指導教授: 蘇喜教授、賴美淑教授. 畢業年度: 102 年.
4. **Huang LY**, Shau WY, Yeh HL, Chen TT, Hsieh JY, Su S, Lai MS. A model measuring therapeutic inertia and the associated factors among diabetes patients: A nationwide population-based study in Taiwan. *J Clin Pharmacol*. 2015 Jan;55(1):17-24. doi: 10.1002/jcph.367. [SCI]
5. **Huang LY**, Yeh HL, Yang MC, Shau WY, Su S, Lai MS. Therapeutic Inertia and Intensified Treatment in Diabetes Prescription Patterns: A Nationwide Population-Based Study. *J Int Med Res*. 2016 Vol 44, Issue 6, pp. 1263 – 1271. [SCI]
6. 陳宗泰、鄒國英、徐世達、蔡宜蓉、許巍鐘、鍾國彪、**黃莉茵**. 運用修正型德菲法與健保資料庫開發具可行性的兒科品質報告卡指標 (The use of modified Delphi method and health insurance database to develop feasible indicators for pediatric quality report card). *Taiwan J Public Health*. 2017;36(6):613-622.

7. Kao KL, **Huang LY**, Wu YH, Gau CS. Outcomes and Impacts of 10-Year HTA Implementation in Taiwan. *Int J Technol Assess Health Care*. 2019 35 (6): 441-445. [SCI] (通訊作者)
8. O'Rourke Brian, Söderholm Werkö Sophie, Merlin Tracy, **Huang LY**, Schuller Tara. Challenges for Health Technology Assessment: INAHTA Viewpoint. *Int J Technol Assess Health Care*. 2019 Nov 28 : 1-4. [Online ahead of print] [SCI]
9. Chen TT, Hsueh YA, Liaw CK, Shih LN, **Huang LY**. Does public report card matter? A 10-year interrupted time series analysis on total knee replacement. *Eur J Public Health*. 2020 Feb 1;30(1):4-9. doi: 10.1093/eurpub/ckz112. [SCI]
10. **Huang LY**, Gau CS. Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan. *Int J Technol Assess Health Care*. 2020 Dec 21;37:e26. [SCI]
11. **Huang LY**, Chen TT, Yang MC, Shau WY, Su S, Lai MS. Trace analysis of therapeutic inertia and subsequent hemoglobin A1c outcomes in a 2-year cohort study. *Eur Rev Med Pharmacol Sci*. 2021 May;25(9):3499-3506. [SCI]
12. Hsieh ST, Ho HF, Tai HY, Chien LC, Chang HR, Chang HP, Huang YW, Huang JJ, Lien HJ, **Huang LY***, Lee PC*. Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System. *Eur Rev Med Pharmacol Sci*. 2021 Nov;25(21):6548-6556. [SCI] (通訊作者)
13. Chen KA, **Huang LY***, Gau CS*. Patient Involvement in the Health Technology Assessment Process in Taiwan. *Front Med Technol*. 2022 Jan 21;3:732160. [SCI] (通訊作者)
14. Tsai HY, Huang YW, Chang SY, **Huang LY***, Lin CJ*, Lee PC*. The reimbursement coverage decisions and pricing rules for medical devices in Taiwan. *GMS Health Innov Technol*. 2022 Mar 16;16:Doc02. doi: 10.3205/hta000134. (通訊作者)
15. Perleth M, Di Bidino R, **Huang LY**, Jones L, Mujoomdar M, Myles S, Pichon-Riviere A,

Sabirin J, Schuller T, Washington J. Disruptive technologies in health care disenchanted: a systematic review of concepts and examples. *Int J Technol Assess Health Care*. 2022 May 16;38(1):e70. [SCI]

16. Holtorf AP, Danyliv A, Krause A, Hanna A, Venable Y, Mattingly TJ 2nd, **Huang LY**, Pierre M, Silveira Silva A, Walsh D. Ethical and legal considerations in social media research for health technology assessment: conclusions from a scoping review. *Int J Technol Assess Health Care*. 2023 Oct 16;39(1):e62. doi: 10.1017/S0266462323000399. PMID: 37842838.

17. Holtorf AP, Danyliv A, **Huang LY**, Venable Y, Hanna A, Krause A, Pierre M, Walsh D, Silveira Silva A, Lee SH, Mattingly TJ 2nd. Using social media research in health technology assessment: stakeholder perspectives and scoping review. *Int J Technol Assess Health Care*. 2023 Sep 21;39(1):e63. doi: 10.1017/S0266462323002593. PMID: 37732455. [SCI]

三高族群用藥之新複方新藥之藥品給付評估及健保收載
Assessment of Reimbursement and Inclusion in NHI for Novel Combination
Medications in the Chronic Disease Population (HTA Perspective)

黃莉茵

財團法人醫藥品查驗中心醫藥科技評估組 組長

2020年由國際官方醫療科技評估組織網絡(The International Network of Agencies for Health Technology Assessment, INAHTA)和醫療科技評估國際協會(Health Technology Assessment International, HTAi)共同領導的國際聯合作小組，制定出國際公認的新醫療科技評估(Health Technology Assessment, 以下簡稱HTA)定義 [1]。HTA的定義為「HTA包含多重領域相關的流程(multidisciplinary process)，利用明確方法(explicit methods)，評估醫療科技在其生命週期之不同時間點的價值。其目的是提供決策者進行決策時的實證依據，以促進公平、有效與高品質之醫療系統」[1]。

在有限的資源下，醫療科技評估(HTA)為提供科學證據，以實證支持衛生政策的形成，在公平正義的原則下，協助決策者進行醫療資源分配。

本課程將介紹醫療科技評估的定義及台灣藥品支付制度與藥品核價辦法。進而說明醫療科技評估在台灣健保支付制度的展望與挑戰。

In 2020, an international joint task group co-led by the International Network of Agencies for Health Technology Assessment (INAHTA) and Health Technology Assessment International (HTAi) has developed a new and internationally accepted definition of HTA^[1].

"HTA is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system."^[1]

With constrained resources, particularly concerning universal health coverage, HTA offers vital scientific evidence that underpins the development of health policies. It aids decision-makers in distributing medical resources fairly and justly, in accordance with the principles of equity and justice.

This course will outline the definition of HTA and explore its role in the appraisal process. Additionally, it will examine the future opportunities and challenges of HTA within Taiwan's National Health Insurance system.

Reference

- [1] O'Rourke B, Oortwijn W, Schuller T; International Joint Task Group. The new definition of health technology assessment: A milestone in international collaboration. *Int J Technol Assess Health Care*. 2020 Jun;36(3):187-190.